<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01195376</url>
  </required_header>
  <id_info>
    <org_study_id>CBEZ235A1101</org_study_id>
    <nct_id>NCT01195376</nct_id>
  </id_info>
  <brief_title>A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Study of BEZ235, Administered Orally in Adult Japanese Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      In this study, BEZ235 will be administered to adult patients with advanced solid tumors whose&#xD;
      disease has progressed despite standard therapy or for whom no standard therapy exists. The&#xD;
      trial will confirmed the safety and tolerability and determine the MTD of BEZ235 in Japanese&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish Maximum tolerate dose (MTD)</measure>
    <time_frame>Every week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by type, frequency and severity of adverse events</measure>
    <time_frame>Every week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by RECIST</measure>
    <time_frame>Every 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the PK profiles</measure>
    <time_frame>Every 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the biomarkers</measure>
    <time_frame>Every 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>BEZ235 Dose Escalation once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral BEZ235 once daily (q.d.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BEZ Dose escalation twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral BEZ235 twice daily (b.i.d.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BEZ235</intervention_name>
    <arm_group_label>BEZ Dose escalation twice daily</arm_group_label>
    <arm_group_label>BEZ235 Dose Escalation once daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with histologically-confirmed, advanced unresectable solid tumors who have&#xD;
             progressed on (or not been able to tolerate) standard therapy or for whom no standard&#xD;
             anticancer therapy exists.&#xD;
&#xD;
          2. At least one measurable lesion as defined by RECIST criteria for solid tumors.&#xD;
&#xD;
          3. Age ≥ 20&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group Performance Status (ECOG P.S.) of ≤ 2&#xD;
&#xD;
          5. Life expectancy of ≥ 12 weeks&#xD;
&#xD;
          6. Patients must have the laboratory values Patients in the expansion part of this study&#xD;
             have to meet the following criteria in addition to the criteria described above.&#xD;
&#xD;
          7. Availability of a representative tumor tissue specimen (either archival tumor or fresh&#xD;
             tumor biopsy) for pre-screening.&#xD;
&#xD;
          8. Patients whose molecular status proved to meet the criteria (PIK3CA&#xD;
             mutation/amplification and/or PTEN mutation and/or low/null PTEN expression) during&#xD;
             pre-screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have brain metastases or who have signs/symptoms attributable and have&#xD;
             not been assessed with radiologic imaging to rule out the presence of brain metastases&#xD;
&#xD;
          2. Patients with any peripheral neuropathy ≥ CTCAE grade 2&#xD;
&#xD;
          3. Patients with unresolved diarrhea ≥ CTCAE grade 2&#xD;
&#xD;
          4. Patients with a history of photosensitivity reactions to other drugs&#xD;
&#xD;
          5. Women of child-bearing potential who are pregnant or breast feeding or adults of&#xD;
             reproductive potential not employing an effective method of birth control. Barrier&#xD;
             contraceptives must be used throughout the trial in both sexes. Women of child-bearing&#xD;
             potential, defined as sexually mature women who have not undergone a hysterectomy or&#xD;
             who have not been naturally postmenopausal for at least consecutive 1 years (i.e., who&#xD;
             has had menses any time in the preceding consecutive 2 years), must have a negative&#xD;
             serum pregnancy test ≤ 7 days prior to starting BEZ235.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kobe-city</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yufu</city>
        <state>Oita</state>
        <zip>879-5593</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=11645</url>
    <description>Results for CBEZ235A1101 can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>September 2, 2010</study_first_submitted>
  <study_first_submitted_qc>September 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2010</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PI3K</keyword>
  <keyword>mTOR</keyword>
  <keyword>Advanced solid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dactolisib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

